Safety concerns and health benefits associated with oral contraception

被引:133
作者
Burkman, R
Schlesselman, JJ
Zieman, M
机构
[1] Baystate Med Ctr, Dept Obstet & Gynecol, Springfield, MA 01199 USA
[2] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Fox Canc Res,Div Biostat, Miami, FL 33152 USA
[3] Emory Univ, Sch Med, Dept Obstet & Gynecol, Atlanta, GA 30322 USA
关键词
oral contraceptives; cardiovascular effects; noncontraceptive health benefits; neoplastic effects;
D O I
10.1016/j.ajog.2004.01.061
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Since the introduction of hormonal contraceptives in the 1960s, there have been a variety of both health bQnefits and safety concerns attributed to their use. In most instances, the noncontraceptive benefits of oral contraceptives (OCs) outweigh the potential cardiovascular risks. In fact, the probability of a patient experiencing a cardiovascular event while taking a low-dose OC is very low. However, smoking, hypertension, obesity, and diabetes are risk factors that must be taken into account when prescribing OCs. The neoplastic effects of hormonal contraceptives have been extensively studied, and recent meta-analyses indicate that there is a reduction in the risk of endometrial and ovarian cancer, a possible small increase in the risk for breast and cervical cancer, and an increased risk of liver cancer. Finally, many women will experience noncontraceptive health benefits with OCs that expand far beyond pregnancy prevention. Some of these benefits include reduction in menstrual-related symptoms, fewer ectopic pregnancies, a possible increase in bone density, and possible protection against pelvic inflammatory disease. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:S5 / S22
页数:18
相关论文
共 108 条
[1]   RETRACTED: An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon® (Retracted Article) [J].
Affandi, B .
CONTRACEPTION, 1998, 58 (06) :99S-107S
[2]   Activated protein C resistance assay when applied in the general population [J].
Altes, A ;
Souto, JC ;
Mateo, J ;
Borrell, M ;
Fontcuberta, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 176 (02) :358-359
[3]  
Bartholomew JS, 1997, CANCER RES, V57, P937
[4]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596
[5]   A CASE-CONTROL STUDY OF BENIGN OVARIAN-TUMORS [J].
BOOTH, M ;
BERAL, V ;
MACONOCHIE, N ;
CARPENTER, L ;
SCOTT, C .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1992, 46 (05) :528-531
[6]   Oral contraceptives: Current status [J].
Burkman, RT .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2001, 44 (01) :62-72
[7]  
Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5
[8]   Cardiovascular disease: Pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke [J].
Castelli, WP .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (06) :S349-S356
[9]   PROSTAGLANDINS IN PRIMARY DYSMENORRHEA - COMPARISON OF PROPHYLACTIC AND NONPROPHYLACTIC TREATMENT WITH IBUPROFEN AND USE OF ORAL-CONTRACEPTIVES [J].
CHAN, WY ;
DAWOOD, MY ;
FUCHS, F .
AMERICAN JOURNAL OF MEDICINE, 1981, 70 (03) :535-541
[10]  
Charreau I, 1993, Eur J Cancer Prev, V2, P147, DOI 10.1097/00008469-199303000-00007